SANTHERA PHARMACEUTICALS DEUTS has a total of 13 patent applications. Its first patent ever was published in 2001. It filed its patents most often in EPO (European Patent Office), WIPO (World Intellectual Property Organization) and United States. Its main competitors in its focus markets organic fine chemistry, pharmaceuticals and measurement are VIROSTATICS SRL, CELLULAR GENOMICS INC and AFFECTIS PHARMACEUTICALS AG.
# | Country | Total Patents | |
---|---|---|---|
#1 | EPO (European Patent Office) | 8 | |
#2 | WIPO (World Intellectual Property Organization) | 3 | |
#3 | United States | 2 |
# | Industry | |
---|---|---|
#1 | Organic fine chemistry | |
#2 | Pharmaceuticals | |
#3 | Measurement | |
#4 | Optics | |
#5 | Machines |
# | Technology | |
---|---|---|
#1 | Heterocyclic compounds | |
#2 | Therapeutic chemical compounds | |
#3 | Analysing materials | |
#4 | Optical systems | |
#5 | Unspecified technologies |
# | Name | Total Patents |
---|---|---|
#1 | Nordhoff Sonja | 10 |
#2 | Cerezo-Galvez Silvia | 10 |
#3 | Feurer Achim | 9 |
#4 | Edwards Paul John | 9 |
#5 | Matassa Victor Giulio | 8 |
#6 | Lopez-Canet Meritxell | 6 |
#7 | Rummey Christian | 6 |
#8 | Thiemann Meinolf | 5 |
#9 | Hill Oliver | 5 |
#10 | Rosenbaum Claudia | 4 |
Publication | Filing date | Title |
---|---|---|
EP1623983A1 | Heterocyclic compounds useful as DPP-IV inhibitors | |
EP1604989A1 | DPP-IV inhibitors | |
EP1604662A1 | 1-¬(3R)-Amino-4-(2-fluoro-phenyl)-butyl|-pyrrolidine-(2R)-carboxylic acid benzyl amine derivatives and related compounds as dipeptidyl peptidase IV (DPP-IV) inhibitors for the treatment of type 2 diabetes mellitus | |
EP1604980A1 | DPP-IV inhibitors | |
EP1598341A1 | DPP-IV inhibitors | |
EP1259796A1 | Spr sensor system |